© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
April 15, 2008
Most patients are successfully treated using PDE5 inhibitors, but if treatment failure occurs, physicians have many therapeutic options at their disposal; these options are outlined by the authors.
Lawrence Eichenfield, MD: Phase 3 Trial Data on Ruxolitinib for Atopic Dermatitis
Karan Lal, DO: Relationship Between Psoriasis and the Skin, Gut Microbiome
Karan Lal, DO: Psoriasis Treatment Advances, Spesolimab for Generalized Pustular Psoriasis